Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARITIME-CV
NL-OMON59039Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Oct 2025
- Modality
- Peptide-Protein Conjugates → Peptide Conjugates → Peptides, Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease, obesity and Overweight comparing Maridebart cafraglutide + standard of care with Placebo + standard of care (2 arms). Primary endpoints: 3-point major adverse cardiovascular events and 5-point major adverse cardiovascular events. Started Oct 2025; status: active, not recruiting.
02
Drugs
maridebart cafraglutide
03
Conditions
atherosclerotic diseaseobesityOverweight
Beyond the preview
Go deeper on NL-OMON59039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59039.